Exact Sciences에 대한 매도 수량은 투자자에게 Exact Sciences의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Exact Sciences (NASDAQ:EXAS) 주식, 공매도 수량 보고

Exact Sciences

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

News

Movers

$BTC

AVGO

BNTX

CHWY

EXAS

FSLR

MSTR

ORCL

ROKU

SMMT

WOOF

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식은 회사가 $2억 3,500만의 순수익을 올렸다고 발표한 후 98.32% 급등했다.

츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)

ALNY

CHRW

COKE

CVNA

DASH

DXCM

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Biotech

Earnings

Health Care

After-Hours Center

이그젝트 사이언스(NASDAQ:EXAS)의 주가는 회사가 수요일 2분기 재무 결과를 발표한 후 급등했다. 보고서의 세부 사항은 다음과 같다. 주요 정보: 대장암 조기발견 및 예방에 초점을 둔 분자진단 회사인 이그젝트 사이언스(Exact Sciences)는 분기별 주당 손실을 9센트로 보고했는데, 이는 분석가들의 합의된 손실 추정치인 32센트를 71.88%나 앞선 것이다.

이그젝트 사이언스: 강력한 제2분기 순이익과 매출 발표 후 시간외 거래에서 주가 급등

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a <a href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results">look at the details.  </a>
The Details: Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
&#8220;The Exact Sciences&#8217; team is helping eradicate cancer while strengthening our platform and growing our business efficiently,&#8221; said Kevin Conroy, CEO of Exact Sciences. 
&#8220;During the third quarter, we delivered test results to more patients than ever before, improved profitability, and achieved key milestones in our pipeline of innovative cancer diagnostics. While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; Conroy added. 
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41715442/trump-media-stock-volatile-on-election-eve-as-polls-betting-markets-predict-tight-white-ho">Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race</a>
Outlook:&nbsp;Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion to $2.75 billion, below the $2.83 billion estimate. 
EXAS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Exact Sciences shares are down 27.98% after-hours at $51.50 at the time of publication Tuesday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41719896/alibaba-layoffs-hit-metaverse-division-will-the-chinese-e-commerce-giant-double-down-on-ai">Alibaba Layoffs Hit Metaverse Division: Will The Chinese E-Commerce Giant Double-Down On AI?&nbsp;</a></li>
</ul>
Photo: Courtesy of Exact Sciences Corporation

Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates

WIIM

Exact Sciences shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

Guidance

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. The company reported quarterly sales of $709.00 million which missed the analyst consensus estimate of $717.66 million by 1.21 percent. This is a 12.84 percent increase over sales of $628.34 million the same period last year.

Earnings Misses

Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate

Bernstein analyst Eve Burstein maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $75 to $90.

Price Target

Analyst Ratings

Bernstein Maintains Outperform on Exact Sciences, Raises Price Target to $90

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $79.86, with a high estimate of $95.00 and a low estimate of $67.00. Experiencing a 1.81% decline, the current average is now lower than the previous average price target of $81.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1730206817_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Exact Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Exact Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>About Exact Sciences</h2>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Exact Sciences's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 12.41%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's net margin excels beyond industry benchmarks, reaching -2.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exact Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.5%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Exact Sciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.24%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.87, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $75 to $95.

Canaccord Genuity Maintains Buy on Exact Sciences, Raises Price Target to $95

Exact Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) short percent of float has risen 13.11% since its last report. The company recently reported that it has 16.42 million shares sold short, which is 8.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Exact Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728491413_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exact Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exact Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Exact Sciences's peer group average for short interest as a percentage of float is 5.78%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(EXAS) - Analyzing Exact Sciences's Short Interest

On Friday, the FDA approved Exact Sciences Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus test, the company&#8217;s next-generation <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41181141/fda-approves-exact-sciences-cologuard-plus-test-setting-a-new-benchmark-in-non-invasive-colorectal" rel="noreferrer noopener">multi-target stool DNA test</a>.
The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer (CRC).
FDA approval was based on findings from the pivotal BLUE-C study, one of the largest prospective, head-to-head studies ever conducted in CRC screening.
Among the subset of nearly 19,000 average-risk participants, the Cologuard Plus test demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity with no findings on colonoscopy.
Results from BLUE-C also show the Cologuard Plus test significantly outperformed an independent fecal immunochemical test for overall CRC sensitivity, treatable-stage CRC (stages I-III) sensitivity, high-grade dysplasia sensitivity, and advanced precancerous lesion sensitivity.
The Cologuard Plus test will build on the Cologuard&nbsp;test, which has been used more than 17 million times.
The&nbsp;Cologuard test is a first-line colorectal cancer screening test for adults age 45 or older at average risk for the disease.
Upon launch in 2025, the Cologuard Plus test will be supported by Exact Sciences&#8217; commercial organization ExactNexus technology platform for orders from over 350 health systems.
The non-invasive test is anticipated to be covered by Medicare.
The Cologuard Plus test demonstrates 91% specificity, including non-advanced findings, 93% specificity, including no findings, and 94% specificity when age-weighted to the U.S. population with no findings on colonoscopy.
In July this year, the FDA approved&nbsp;Guardant Health Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40006571/guardant-healths-shield-blood-test-approved-by-fda-as-a-primary-screening-option-clearing-path-for" rel="noreferrer noopener">are at average risk for the disease</a>.
The company says it is the first blood test approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield like all other non-invasive methods recommended <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40018447/fda-greenlights-guardant-healths-shield-blood-test-analyst-cautious-on-adoption" rel="noreferrer noopener">in screening guidelines</a>.
Price Action: EXAS stock is up 1.94% at $67.70 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41184042/bristol-myers-10b-cancer-drug-opdivo-scores-expanded-use-fda-approval-for-lung-cancer-in-pre-and-" target="_blank" rel="noreferrer noopener">Bristol Myers&#8217; $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting</a>.</li>
</ul>

Large Cap

General

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test

Exact Sciences Says FDA Approves Exact Sciences' Cologuard Plus Test, Setting New Benchmark In Non-Invasive Colorectal Cancer Screening, Company Expects To Launch Cologuard Plus Test With Medicare Coverage And Guideline Inclusion In 2025

In the latest quarter, 7 analysts provided ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.0, along with a high estimate of $85.00 and a low estimate of $67.00. Highlighting a 7.78% decrease, the current average has fallen from the previous average price target of $83.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727802065_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Exact Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
<h3>Financial Insights: Exact Sciences</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 12.41%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exact Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Exact Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of -0.24%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.87.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Exact Sciences

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $72 to $80.

Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $80

Raymond James analyst Andrew Cooper reiterates Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Market Perform.

Reiteration

Raymond James Reiterates Market Perform on Exact Sciences

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

ILMN

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EXAS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Exact Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $117,000, and 8, calls, for a total amount of $372,081.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $85.0 for Exact Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total volume of 2,211.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Exact Sciences's big money trades within a strike price range of $55.0 to $85.0 over the last 30 days.
<h3>Exact Sciences Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726511438_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$65.00</td>
<td>$117.0K</td>
<td>10</td>
<td>300</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.0</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$67.50</td>
<td>$59.0K</td>
<td>4.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$14.7</td>
<td>$14.5</td>
<td>$14.6</td>
<td>$55.00</td>
<td>$58.3K</td>
<td>1.8K</td>
<td>279</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$2.4</td>
<td>$2.75</td>
<td>$85.00</td>
<td>$55.0K</td>
<td>131</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.7</td>
<td>$10.4</td>
<td>$10.9</td>
<td>$62.50</td>
<td>$52.3K</td>
<td>421</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Exact Sciences</h3>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
<h3>Exact Sciences's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,695,220, the price of EXAS is up by 1.8%, reaching $66.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 44 days from now.</li>
</ul>
<h3>What The Experts Say On Exact Sciences</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $78.33333333333333.
<ul>
<li>An analyst from Wells Fargo downgraded its action to Overweight with a price target of $75. </li>
<li>Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Exact Sciences, targeting a price of $75. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Exact Sciences, targeting a price of $85. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Exact Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

Exact Sciences Unusual Options Activity For September 16

Exas Science shares are trading higher after the company announced data for its blood-based colorectal cancer screening test.

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation titled, "Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort."

Exact Sciences Unveils Data on Blood-Based Colorectal Cancer Test at ESMO

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares rocketed 98.32% after the company announced it raised&nbsp;<a href="https://www.benzinga.com//node/40833208" target="_blank" rel="noreferrer noopener">$235 million&nbsp;in net proceeds</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock gained 31.77% in the last week after GSK halted development of the Herpes Simplex Virus Vaccine, clearing the path for other contenders like Moderna and BioNTech.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock jumped 28.38% as several analysts raised<a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener"> the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) stock escalated 21.37%. The stock possibly jumped amid sympathy with Petco Health and Wellness Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) after the company <a href="https://www.benzinga.com//node/40822147" target="_blank" rel="noreferrer noopener">reported&nbsp;financial results</a>.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares increased 20.81%. The stock may be up amid a <a href="https://www.benzinga.com//node/40852990" target="_blank" rel="noreferrer noopener">rebound in some chip stocks</a>.</li>
<li>Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares gained 20.50% after Raymond James initiated coverage on the stock with an Outperform rating and announced <a href="https://www.benzinga.com/quote/arm/analyst-ratings" target="_blank" rel="noreferrer noopener">a $160 price target</a>.</li>
<li>MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock upped 18.74% after the company announced purchasing 18,300 bitcoins (CRYPTO: BTC/USD).</li>
<li>Kinross Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) shares increased 17.14% after the company announced it completed a Preliminary Economic <a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">Assessment for the Great Bear project</a>.</li>
<li>Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) stock gained 17.10% in the last week on continued strength after a recently announced multi-year partnership with Charter to integrate linear video and streaming services to enhance flexibility and value in video bundles.</li>
<li>Vertiv Holdings, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) stock upped 17.02%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40869968/moderna-tyson-foods-and-adobe-are-among-top-10-large-cap-stock-losers-last-week-sep-8-sep-14-are-t">Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Chewy

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $75 price target.

Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target

Exact Sciences shares are trading higher after Piper Sandler raised its price target on the stock from $75 to $85.

Canaccord raised the firm's price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bull...

Exact Sciences price target raised to $95 from $75 at Canaccord

Here are the major earnings after the close today

Notable companies reporting after the market close, with earnings consensus, include Microchip Technology (MCHP), consensus 43c… Supermicro (SMCI),...

Notable companies reporting after market close

Pre-earnings options volume in EXACT Sciences (EXAS) is 9.0x normal with calls leading puts 19:7. Implied volatility suggests the market is anticip...

EXACT Sciences options imply 10.2% move in share price post-earnings

Exact Sciences GAAP EPS of -$0.21 misses by $0.03, revenue of $709M misses by $7.99M

Earnings Snapshot: Exact Sciences misses Q3 estimates, cuts expectations for the full year

Reports Q3 revenue $709M, consensus $717.66M. "The Exact Sciences (EXAS)' team is helping eradicate cancer while strengthening our platform and gro...

Exact Sciences reports Q3 EPS (21c), consensus (21c)

Previous view $2.81B-$2.85B. Cuts FY24 adjusted EBITDA view to $310M-$320M from $335M-$355M. Published first on TheFly – the ultimate source for re...

Exact Sciences cuts FY24 revenue view to $2.73B-$2.75B, consensus $2.83B

Exact Sciences plummets 28% on revenue guidance cut, Q3 misses

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Qualys (QLYS) up 18.9% Revolv...

Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut

AVNW

BBAI

BCSF

CGBD

CPNG

EOSE

FYBR

GMED

GPOR

IGIC

IRBT

JKHY

LAAC

LUMN

MASI

MCHP

MEGEF

MGNX

MRCY

NCMI

PAAS

PAYS

QLYS

RARE

RVLV

RYAM

RYTM

SMCI

SNDX

STKL

SWIM

TFPM

TMCI

TRVG

TSLX

WTTR

Screenshot 2024-08-30 at 6.27.59 PM

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)

Press Releases

Exact Sciences to Participate in September Investor Conferences

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Schedules Third Quarter 2024 Earnings Call

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

Comments

Exact Sciences

매도 수량

Exact Sciences (NASDAQ:EXAS) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌